Menu

Cesar RAMIREZ

Marly-le-Roi

En résumé

• DMPK&PD Team Leader (Director) with a Ph.D. in Analytical Sciences and more than 12 years of experience in Drug Discovery projects, from early stage, lead optimization including candidate selection, up to the transition into clinical studies.
• Pharmaceutical drug discovery programme co-leader and programme team member representing the DMPK&PD discipline within the immuno-inflammation therapy area, with especial focus on Kinase and BET inhibitors, for oral and topical (dermal) indications.
• Innovative leader that focus on delivery with quality and integrity, always promoting individuals & team development and technical excellence in a safe environment.
• Key driver of the successful implementation of the Quantitative/Translational Pharmacology integrated approach applied to different stages of the drug discovery process.

Mes compétences :
Industrie pharmaceutique
PK/PD
DMPK
Bioanalytical
Biotransformations
Management

Entreprises

  • GlaxoSmithKline - Director

    Marly-le-Roi 2006 - maintenant DMPK&PD expert for Kinase and Epigenetics programmes in the immuno-inflammation therapy area. Management of a team of ten DMPK/PD/Analytical scientists, ensuring efficiency and accountability to deliver high impact solutions to ADME challenges for projects at different stages of the drug discovery process. Provides strategic, scientific and managerial leadership to the overall Quantitative/Translational Pharmacology group. Responsible for the coordination of the quantitative pharmacology sub-teams representing the Biology, Pharmacokinetics and Analytical disciplines supporting and liaising with internal programmes and external collaborations (academic and contract organisations). Milestones achieved: multiple candidate selections and IB contributions for CTA.

  • SGS - CEPHAC (Life Sciences) - DMPK - Study Director

    2003 - 2006 • Bioanalytical Scientist. SGS-CEPHAC, St Benoît, France. Nov 2003 – September 2006.
    Management of projects as a qualified Study Director from Bioanalytical Study Plan to Final Report as Team Leader of a group of 3 to 6 analysts. In charge of the development and validation of LC-MS/MS methods for analysis of drugs from biological matrices in support of pre-clinical and clinical trials under GLP regulations.

Formations

  • GlaxoSmithkline (Stevenage)

    Stevenage 2000 - 2003 • Postdoctoral position. GlaxoSmithKline (GSK). Stevenage, Herts. UK. September 2000 - October 2003. Training in drug discovery and diverse analytical techniques including Mass Spectrometry (MS) & Nuclear Magnetic Resonance (NMR)

  • Université Nantes (Nantes)

    Nantes 1995 - 2000 PhD - Doctorat

    • Ph.D. in Analytical Sciences. University of Nantes, France. June 2000.
    • Diplôme d'Études Approfondies (D. E. A), a post-graduate diploma in project scheduling "Physical-Chemistry and Analytical Chemistry". Université de Nantes, France. June 1996.

Réseau

Annuaire des membres :